Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23695520 | 1.00 | SLC6A4 (0.34) | SLC6A4WRNCYP3A4CYP2D6MAPT | |
| SCHEMBL15156804 | 1.00 | SLC6A4 (0.34) | SLC6A4WRNCYP3A4CYP2D6MAPT | |
| SCHEMBL14295827 | 0.77 | CYP3A4 (0.35) | WRNCYP3A4CYP2D6MAPTCYP2C9 | |
| SCHEMBL20721133 | 0.77 | ALOX5 (0.41) | SLC6A4MAPTCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL12261647 | 0.77 | ALOX5 (0.41) | SLC6A4MAPTCYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL5047579 | 0.76 | — | — | |
| SCHEMBL24803031 | 0.76 | — | — | |
| SCHEMBL25235487 | 0.76 | — | — | |
| SCHEMBL12073836 | 0.75 | LMNA (0.39) | WRNCYP3A4CYP2D6MAPTCYP2C9 | |
| SCHEMBL12261844 | 0.75 | GABBR2 (0.42) | SLC6A4WRNCYP3A4CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CHENGDU BIOBEL COMPANY LIMITED (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2021147123-A1 | COMPOUND HAVING ANTISPORULANT ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | 成都贝诺科成生物科技有限公司 | 2021-07-29 | — | — | WO | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | SLC6A4 4396/4885WRN 3308/4885CYP3A4 2075/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | SLC6A4 4328/4885WRN 2669/4885CYP3A4 1429/4885 |
| US-20230135729-A1 | COMPOUND WITH ANTI-SPORE ACTIVITY AND PHARMACEUTICAL COMPOSITION THEREOF | CASP9, CLPP, CASP1 | SLC6A4 3070/4885WRN 4628/4885CYP3A4 2416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.